Want to see TSE:LOBE full AI Analyst Report?
Lobe Sciences (LOBE) AI Stock Analysis
Lobe Sciences
(CNQX:LOBE)
The score is held down primarily by very weak financial performance, with no TTM revenue, continued losses, and ongoing cash burn. Technical trend strength provides some support, but valuation is poor and there is no earnings call or corporate event data to improve the outlook.
Lobe Sciences (LOBE) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 9.68M
- Dividend Yield
- ―
- Average Volume (3M)
- 144.88K
- Price to Earnings (P/E)
- -2.2
- Beta (1Y)
- 0.49
- Revenue Growth
- ―
- EPS Growth
- 31.00%
- Country
- Canada
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Lobe Sciences Business Overview & Revenue Model
Company Description
Lobe Sciences Ltd. operates as a life sciences entity, primarily focused on the exploration and advancement of psychedelic pharmaceutical compounds. The company is actively engaged in formulating psilocybin-derived therapeutics, combined with N-acety...
How the Company Makes Money
Publicly available, reliably current information needed to describe Lobe Sciences’ present-day revenue model (e.g., active commercial products, recurring service revenues, licensing royalties, or material collaboration income) is null. In general, ea...
Lobe Sciences Financial Statement Overview
Summary
Financial performance is very weak: TTM revenue is $0, profitability remains negative, and cash flow is still burning. The balance sheet is the least concerning element, but thin equity and limited asset support keep the overall financial profile high-risk.
Income Statement
14Very NegativeBalance Sheet
34NegativeCash Flow
16Very Negative| Breakdown | TTM | Nov 2025 | Nov 2024 | Aug 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 136.21K | 840.53K | 0 | 0 |
| Gross Profit | 0 | 0 | 134.45K | 772.83K | -10.22K | 0 |
| EBITDA | -6.89M | -4.27M | -4.12M | -4.40M | -11.96M | -6.16M |
| Net Income | -5.17M | -4.43M | -4.42M | -4.71M | -12.25M | -22.82M |
Balance Sheet | ||||||
| Total Assets | 5.53M | 7.59M | 258.57K | 2.30M | 1.75M | 12.10M |
| Cash, Cash Equivalents and Short-Term Investments | 5.21M | 7.54M | 237.77K | 140.29K | 907.54K | 7.43M |
| Total Debt | 338.40K | 273.35K | 1.75M | 332.64K | 0 | 0 |
| Total Liabilities | 2.33M | 2.70M | 3.37M | 2.46M | 1.30M | 804.70K |
| Stockholders Equity | 1.89M | 2.36M | -3.11M | -160.13K | 445.69K | 11.29M |
Cash Flow | ||||||
| Free Cash Flow | -3.74M | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Operating Cash Flow | -3.74M | -1.42M | -462.29K | -1.72M | -2.73M | -5.04M |
| Investing Cash Flow | -3.78M | 6.56M | 0 | 0 | 1.74M | 1.07M |
| Financing Cash Flow | 1.09M | 514.40K | 563.51K | 950.01K | 753.12K | 4.92M |
Lobe Sciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LOBE, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.37 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LOBE.
Lobe Sciences Peers Comparison
Overall Rating
TSE:LABS49Neutral
TSE:OILS47Neutral- TSE:LOBE47Neutral
TSE:PCLO42Neutral
TSE:AVCN41Neutral
TSE:GWAY41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:LABS | 49Neutral | CAD 27.77M | -5.60 | -13.79% | ― | -6.74% | 43.54% |
| TSE:OILS | 47Neutral | CAD 3.40M | -1.75 | -43.92% | ― | -18.30% | -397.37% |
| TSE:LOBE | 47Neutral | CAD 13.87M | -2.18 | -338.76% | ― | ― | 31.00% |
| TSE:PCLO | 42Neutral | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
| TSE:AVCN | 41Neutral | CAD 14.11M | -3.24 | -108.44% | ― | -0.23% | -142.54% |
| TSE:GWAY | 41Neutral | CAD 10.69M | -3.62 | -35.33% | ― | -1.41% | -78.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:LOBE | Lobe Sciences Ltd | 0.04 | 0.00 | 0.00% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -13.33% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:OILS | Nextleaf Solutions | 0.02 | -0.04 | -66.67% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.16 | -60.38% | |
| TSE:GWAY | Greenway Greenhouse Cannabis Corp. | 0.08 | -0.09 | -52.94% |
Lobe Sciences Corporate Events
Lobe Sciences Raises $2.16 Million in Upsized Private Placement to Advance Sickle Cell Drug
PositiveLobe Sciences has closed an upsized, non-brokered private placement of common shares at $0.085 per share, issuing a total of 25,411,762 shares for gross proceeds of $2.16 million following strong investor demand. The second tranche added 705,882 shar...
Lobe Sciences Upsizes Private Placement to Fund Sickle Cell and Neurology Pipeline
PositiveLobe Sciences has increased the size of its non-brokered private placement of common shares at $0.085, following strong investor demand. After closing a first tranche that raised $2.1 million, the company plans a second tranche that will bring total...
Lobe Sciences Names New CFO to Support Growth and Clinical Pipeline
PositiveLobe Sciences, a clinical-stage biopharmaceutical company developing differentiated therapies for serious unmet medical needs, is advancing a pipeline led by L-130, a conjugated psilocin compound for chronic cluster headache, and S-100 for sickle cel...
Lobe Sciences Raises $2.1 Million to Advance Sickle Cell Drug Toward Clinical Trials
PositiveLobe Sciences Ltd., a Vancouver-based clinical-stage biopharmaceutical company, develops treatments for unmet medical needs via subsidiaries focused on neurological, psychiatric and hematologic disorders. Through Cynaptec Pharmaceuticals it is advanc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026